These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 9734735)

  • 1. Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate.
    Lavin JH; Wittert GA; Andrews J; Yeap B; Wishart JM; Morris HA; Morley JE; Horowitz M; Read NW
    Am J Clin Nutr; 1998 Sep; 68(3):591-8. PubMed ID: 9734735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intraduodenal glucose and fructose on antropyloric motility and appetite in healthy humans.
    Rayner CK; Park HS; Wishart JM; Kong M; Doran SM; Horowitz M
    Am J Physiol Regul Integr Comp Physiol; 2000 Feb; 278(2):R360-6. PubMed ID: 10666136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1).
    Ranganath L; Schaper F; Gama R; Morgan L; Wright J; Teale D; Marks V
    Diabetes Metab Res Rev; 1999; 15(6):390-4. PubMed ID: 10634963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity.
    Ranganath LR; Beety JM; Morgan LM
    Horm Metab Res; 1999 Apr; 31(4):262-6. PubMed ID: 10333081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.
    Flint A; Raben A; Ersbøll AK; Holst JJ; Astrup A
    Int J Obes Relat Metab Disord; 2001 Jun; 25(6):781-92. PubMed ID: 11439290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of intraduodenal fat and glucose on the gut-incretin axis in healthy males.
    Wu T; Rayner CK; Watson LE; Jones KL; Horowitz M; Little TJ
    Peptides; 2017 Sep; 95():124-127. PubMed ID: 28800948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.
    Chaikomin R; Doran S; Jones KL; Feinle-Bisset C; O'Donovan D; Rayner CK; Horowitz M
    Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E504-7. PubMed ID: 15886226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
    Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
    Näslund E; Barkeling B; King N; Gutniak M; Blundell JE; Holst JJ; Rössner S; Hellström PM
    Int J Obes Relat Metab Disord; 1999 Mar; 23(3):304-11. PubMed ID: 10193877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
    Bergmann NC; Lund A; Gasbjerg LS; Meessen ECE; Andersen MM; Bergmann S; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Knop FK
    Diabetologia; 2019 Apr; 62(4):665-675. PubMed ID: 30683945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.
    Herrmann C; Göke R; Richter G; Fehmann HC; Arnold R; Göke B
    Digestion; 1995; 56(2):117-26. PubMed ID: 7750665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility.
    MacIntosh CG; Andrews JM; Jones KL; Wishart JM; Morris HA; Jansen JB; Morley JE; Horowitz M; Chapman IM
    Am J Clin Nutr; 1999 May; 69(5):999-1006. PubMed ID: 10232642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F; Fehmann HC; Göke R; Göke B
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.